A mysterious vaccine company registered to a P.O. box receives $28 million in taxpayer money while being run by former Biden staffers, sparking demands for an immediate investigation into potential corruption and misuse of public funds.
At a Glance
- The National Institutes of Health awarded $28 million to Vaccine Company Inc., a firm founded in 2022 with ties to a former Biden COVID adviser.
- The company has no website, is registered to a P.O. box in Bethesda, Maryland, and has offered inconsistent information about its primary location.
- Key executives, including former Biden adviser Sonya Bernstein and former Pfizer executive Susan Silbermann, do not publicly disclose their roles with the company.
- Senator Joni Ernst has demanded a probe into the company’s operations and the grant’s vetting process, with a report due by March 17.
Shadow Company Receives Millions in Taxpayer Dollars
In a staggering display of government waste that should have every American taxpayer fuming, the National Institutes of Health has handed over $28 million to a virtually unknown entity called Vaccine Company Inc. This so-called company, founded just two years ago in 2022, operates from a P.O. box in Bethesda, Maryland, with virtually no public presence. The firm is supposedly tasked with developing vaccines for West Nile, dengue, and Zika viruses, yet maintains no website and provides conflicting information about where it actually operates, listing different primary locations in California, Maryland, and Massachusetts on various business registration forms.
The company’s leadership raises even more red flags. Its Chief Financial Officer is none other than Sonya Bernstein, a former Biden COVID adviser who appears determined to keep her role with the company under wraps. The CEO position is filled by Susan Silbermann, a former Pfizer executive who similarly does not publicly disclose her connection to Vaccine Company Inc. This lack of transparency from both executives should immediately trigger suspicion about why they’re so reluctant to be associated with a company receiving millions in government funding.
Political Connections Raise Serious Questions
The web of connections between this mysterious vaccine company and the Biden administration suggests something far more troubling than mere coincidence. The firm is reportedly associated with Arch Venture Partners, a biotechnology investment firm, creating a complex network of financial relationships that demands scrutiny. Senator Joni Ernst has rightly called for an investigation into how taxpayer dollars ended up flowing to this shadowy operation, demanding answers about the vetting process that somehow approved such a substantial grant to a company with virtually no track record and dubious operational details.
The company has reportedly been involved in clinical trials for a COVID mRNA vaccine, yet remains virtually invisible to public scrutiny. This striking contrast – receiving millions in taxpayer funding while maintaining almost complete secrecy – exemplifies everything wrong with government spending priorities. Ernst has requested a comprehensive probe into the company’s operations and grant vetting process, with a report due by March 17, which should reveal the full extent of this potentially scandalous misallocation of public resources.
Broader Pattern of NIH Funding Controversies
This questionable grant comes amid broader controversies surrounding NIH funding decisions. Recently, a federal judge issued a temporary restraining order to halt NIH’s decision to cut research grants in 22 states, later expanding it nationwide. The NIH had planned to reduce grants by capping administrative and overhead costs, potentially impacting legitimate research programs at universities across the country. Meanwhile, millions flow freely to a company with a P.O. box address and deep political connections to the previous administration.
Universities have argued that proper funding cuts would lead to layoffs and reduced research programs, affecting critical drug development. Senator Susan Collins criticized the NIH’s planned cap on indirect costs, calling it a “poorly conceived directive” that could result in job losses and halted research. Dr. Elena Fuentes-Afflick has warned of potential layoffs and disrupted medical research due to these funding adjustments. Yet somehow, $28 million was readily available for a mysterious company with Biden administration ties and no public presence.
